ATE550352T1 - Verfahren zur herstellung von hybridantikörper - Google Patents

Verfahren zur herstellung von hybridantikörper

Info

Publication number
ATE550352T1
ATE550352T1 AT02794114T AT02794114T ATE550352T1 AT E550352 T1 ATE550352 T1 AT E550352T1 AT 02794114 T AT02794114 T AT 02794114T AT 02794114 T AT02794114 T AT 02794114T AT E550352 T1 ATE550352 T1 AT E550352T1
Authority
AT
Austria
Prior art keywords
hybrid
antibodies
framework regions
hybrid antibodies
antibody fragments
Prior art date
Application number
AT02794114T
Other languages
English (en)
Inventor
Russell Rother
Dayang Wu
Original Assignee
Alexion Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharma Inc filed Critical Alexion Pharma Inc
Application granted granted Critical
Publication of ATE550352T1 publication Critical patent/ATE550352T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT02794114T 2001-12-03 2002-12-03 Verfahren zur herstellung von hybridantikörper ATE550352T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33659101P 2001-12-03 2001-12-03
PCT/US2002/038450 WO2003048321A2 (en) 2001-12-03 2002-12-03 Hybrid antibodies

Publications (1)

Publication Number Publication Date
ATE550352T1 true ATE550352T1 (de) 2012-04-15

Family

ID=23316785

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02794114T ATE550352T1 (de) 2001-12-03 2002-12-03 Verfahren zur herstellung von hybridantikörper

Country Status (12)

Country Link
US (1) US7399594B2 (de)
EP (2) EP1461428B1 (de)
JP (3) JP4723810B2 (de)
AT (1) ATE550352T1 (de)
AU (1) AU2002359568B2 (de)
CA (1) CA2468744C (de)
CY (1) CY1112843T1 (de)
DK (1) DK1461428T3 (de)
ES (1) ES2384100T3 (de)
PT (1) PT1461428E (de)
SI (1) SI1461428T1 (de)
WO (1) WO2003048321A2 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US7393648B2 (en) * 2001-12-03 2008-07-01 Alexion Pharmaceuticals, Inc. Hybrid antibodies
WO2004005351A2 (en) * 2002-07-04 2004-01-15 Oncomab Gmbh Neoplasm specific antibodies and uses thereof
GB0407315D0 (en) * 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
MXPA06000258A (es) * 2003-07-15 2006-07-03 Cambridge Antibody Tech Moleculas de anticuerpo humano para interleucina-13.
AU2004290085A1 (en) * 2003-11-07 2005-05-26 Curagen Corporation Antibodies against secretoryleukocyte protease inhibitor
DE10353175A1 (de) 2003-11-14 2005-06-16 Müller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper mit fettsenkender Wirkung
EP1531162A1 (de) 2003-11-14 2005-05-18 Heinz Vollmers Antikörper SAM-6, der spezifisch von Adenocarzinom ist, und dessen Verwendungen
EP2221315A1 (de) * 2003-12-04 2010-08-25 Xencor, Inc. Verfahren zur Erzeugung von Proteinvarianten mit erhöhtem Wirtsstranginhalt und Zusammensetzungen davon
CA2550155C (en) * 2003-12-15 2015-03-17 Dendreon Corporation Hla-dr-specific antibodies, compositions and methods
CA2562034A1 (en) * 2004-03-31 2005-10-20 Jin Lu Method and apparatus for analyzing and generating human antibody amino acid and nucleic acid sequences
US20060263787A1 (en) * 2004-05-10 2006-11-23 Evans Glen A Immunoglobulin-like variable chain binding polypeptides and methods of use
GB0414886D0 (en) 2004-07-02 2004-08-04 Neutec Pharma Plc Treatment of bacterial infections
WO2006138739A2 (en) 2005-06-17 2006-12-28 Tolerx, Inc. Ilt3 binding molecules and uses therefor
FR2892724B1 (fr) * 2005-11-02 2008-01-04 Lab Francais Du Fractionnement Anticorps cytotoxiques diriges contre des anticorps inhibiteurs du facteur viii.
AU2007345745C1 (en) 2006-06-19 2013-05-23 Merck Sharp & Dohme Corp. ILT3 binding molecules and uses therefor
CN101970488B (zh) 2007-12-07 2014-06-18 津莫吉尼蒂克斯公司 对il-31特异的人源化抗体分子
EP2245064B1 (de) * 2007-12-21 2014-07-23 Medimmune Limited BINDUNGSELEMENTE FÜR INTERLEUKIN-4-REZEPTOR ALPHA (IL-4Ralpha)
WO2009079793A1 (en) * 2007-12-21 2009-07-02 National Research Council Of Canada Non-aggregating human vh domains
WO2009131605A2 (en) * 2008-01-28 2009-10-29 Thomas Jefferson University Fusion partner cell line for preparation of hybrid cells expressing human antibodies
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
US20110313134A1 (en) * 2008-11-06 2011-12-22 Alexion Pharmaceuticals, Inc. Engineered antibodies with reduced immunogenicity and methods of making
US8569460B2 (en) * 2009-03-25 2013-10-29 Vet Therapeutics, Inc. Antibody constant domain regions and uses thereof
US9616120B2 (en) * 2010-03-04 2017-04-11 Vet Therapeutics, Inc. Monoclonal antibodies directed to CD20
US8652470B2 (en) * 2010-03-04 2014-02-18 Vet Therapeutics, Inc. Monoclonal antibodies directed to CD52
ES2961381T3 (es) 2010-06-19 2024-03-11 Memorial Sloan Kettering Cancer Center Anticuerpos anti-GD2
CN102251013A (zh) * 2011-02-22 2011-11-23 北京市肿瘤防治研究所 一个识别肿瘤起始细胞的抗体和抗原及其应用
ME03486B (de) 2012-10-12 2020-01-20 Medimmune Ltd Pyrrolobenzodiazepine und Konjugate davon
PT2906296T (pt) 2012-10-12 2018-06-01 Medimmune Ltd Conjugados de pirrolobenzodiazepina-anticorpo
EP2906298B1 (de) * 2012-10-12 2018-10-03 ADC Therapeutics SA Pyrrolobenzodiazepin-antikörper-konjugate
RU2680267C2 (ru) 2013-03-15 2019-02-19 Мемориал Слоан Кеттеринг Кэнсер Сентер Высокоаффинные антитела к gd2
WO2015052534A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
KR20200032243A (ko) 2017-02-08 2020-03-25 에이디씨 테라퓨틱스 에스에이 피롤로벤조디아제핀-항체 컨주게이트
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
PT3612537T (pt) 2017-04-18 2022-08-29 Medimmune Ltd Conjugados de pirrolobenzodiazepina
EP3612234B1 (de) 2017-04-20 2024-03-13 ADC Therapeutics SA Kombinationstherapie mit anti-axl-antikörper-arzneimittel-konjugat
UA127900C2 (uk) 2017-06-14 2024-02-07 Ейдісі Терапьютікс Са Схема дозування для введення adc до cd19
DK3668874T3 (da) 2017-08-18 2022-02-14 Medimmune Ltd Pyrrolobenzodiazepin-konjugater
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4470925A (en) * 1982-05-05 1984-09-11 E. I. Du Pont De Nemours And Company Immunoglobulin half-molecules and process for producing hybrid antibodies
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
WO1993011236A1 (en) 1991-12-02 1993-06-10 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
US5643756A (en) 1992-08-28 1997-07-01 The Public Health Research Institute Of The City Of New York, Inc. Fusion glycoproteins
CA2145063A1 (en) 1992-09-22 1994-03-31 Cambridge Genetics Limited Recombinant viruses displaying a nonviral polypeptide on their external surface
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
GB9416721D0 (en) 1994-08-18 1994-10-12 Short Brothers Plc A bias yarn assembly forming device
AU725609C (en) 1995-08-18 2002-01-03 Morphosys Ag Protein/(poly)peptide libraries
EP0888125B1 (de) * 1996-03-20 2004-05-26 Immunomedics, Inc. GLYKOSYLIERTE IgG ANTIKÖRPER
US5908925A (en) * 1996-06-27 1999-06-01 Exocell, Inc. Genetically engineered immunoglobulins with specificity for glycated albumin
US20030109680A1 (en) * 2001-11-21 2003-06-12 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
US7117096B2 (en) * 2001-04-17 2006-10-03 Abmaxis, Inc. Structure-based selection and affinity maturation of antibody library
US7321026B2 (en) * 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
CA2460587A1 (en) * 2001-09-20 2003-03-27 Alexion Pharmaceuticals, Inc. Anti-pdgf antibodies and methods for producing engineered antibodies
US20030190705A1 (en) * 2001-10-29 2003-10-09 Sunol Molecular Corporation Method of humanizing immune system molecules

Also Published As

Publication number Publication date
CA2468744A1 (en) 2003-06-12
EP1461428A2 (de) 2004-09-29
JP5054058B2 (ja) 2012-10-24
AU2002359568B2 (en) 2008-02-21
JP2009153527A (ja) 2009-07-16
US7399594B2 (en) 2008-07-15
EP1461428A4 (de) 2005-05-25
CA2468744C (en) 2013-05-14
AU2002359568A1 (en) 2003-06-17
EP1461428B1 (de) 2012-03-21
WO2003048321A3 (en) 2003-10-16
CY1112843T1 (el) 2016-02-10
JP4723810B2 (ja) 2011-07-13
PT1461428E (pt) 2012-05-29
JP2005511706A (ja) 2005-04-28
EP2298817A1 (de) 2011-03-23
WO2003048321A2 (en) 2003-06-12
DK1461428T3 (da) 2012-06-04
SI1461428T1 (sl) 2012-07-31
US20030219861A1 (en) 2003-11-27
JP2012144551A (ja) 2012-08-02
ES2384100T3 (es) 2012-06-29

Similar Documents

Publication Publication Date Title
ATE550352T1 (de) Verfahren zur herstellung von hybridantikörper
WO2004108889A3 (en) Hybrid antibodies
DK1414858T3 (da) Kamelid-enkeltkæde-VHH-antistoffer, fremgangsmåde til fremstilling heraf i et pattedyr samt anvendelser heraf
DE60231316D1 (de) VERWENDUNG VON BISPEZIFISCHEN ANTIKÖRPERN GEGEN EINEN AKTIVIERENDEN REZEPTOR FcEpsilonRI UND GEGEN EINEN INHIBIERENDEN REZEPTOR OX2Ra (CD200Ra) ZUR REGULIERUNG DER IMMUNANTWORTEN
ITRM20030601A1 (it) Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
CA2469833A1 (en) Canine immunoglobulin variable domains, caninized antibodies, and methods for making and using them
DE69842174D1 (de) Verfahren zur Herstellung humanisierter Antikörper durch randomisierte Mutagenese
WO2003100008A3 (en) Neutralizing human anti-igfr antibody
ATE368095T1 (de) Verfahren zur herstellung von mitteldistillaten
ATE459706T1 (de) Monoklonales antikörper gegen das hcv kernantigen
HK1071898A1 (en) Recombinant antibodies, and compositions and methods for making and using the same
IL213524A0 (en) Method for removing blood group antigens in serum
ATE509955T1 (de) Humanisierte kollagen-antikörper und damit verbundene verfahren
DE60232618D1 (de) Mikrofluidische Vorrichtung, Verfahren zur Herstellung und Verwendung desselben
WO2003010201A3 (en) Blood group antigen fusion polypeptides and methods of use thereof
ATE297430T1 (de) Verfahren zur herstellung von tannin und seine verwendung
DE60332111D1 (de) Transgene huftiere, die zur produktion von menschlichen antikörpern fähig sind
ATE358172T1 (de) Verfahren zur herstellung von olefinen.
ATE423467T1 (de) Verfahren zur herstellung von genetisch modifizierten antikörperproduzierenden zelllinien mit verbesserten antikörpereigenschaften